Stuart Orkin Awarded Breakthrough Prize in Life Sciences - Takeaways - MDSpire

Stuart Orkin Awarded Breakthrough Prize in Life Sciences

Stuart H. Orkin, MD, Investigator at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, David G. Nathan Distinguished Professor, Harvard Medical School and Investigator, Howard Hughes Medical Institute, has been honored with The Breakthrough Prize in Life Sciences for discovering how the body turns off fetal hemoglobin after birth, a finding that led to a new treatment strategy for sickle cell disease. Dr. Orkin shares the prize with SweeLay Thein, Investigator at the National Institutes of Health (NIH).

  • By

  • April 19, 2026

  • 6 min

Share

  • 1

    Stuart H. Orkin, MD, received The Breakthrough Prize in Life Sciences for his discovery related to fetal hemoglobin and sickle cell disease treatment.

  • 2

    Orkin identified BCL11A as a key regulator that turns off fetal hemoglobin after birth, providing a target for new therapies.

  • 3

    His research led to FDA-approved gene-editing therapies that reactivate fetal hemoglobin, significantly improving outcomes for sickle cell patients.

  • 4

    Orkin's work has been recognized with numerous awards, including the Warren Alpert Foundation Prize and the Canada Gairdner International Award.

  • 5

    He has authored over 500 publications and is a member of several prestigious scientific academies, highlighting his contributions to hematology.

Original Source(s)

Stuart Orkin Awarded Breakthrough Prize in Life Sciences

  • by

  • April 19, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies

  • May 13, 2026

  • 3 min
Complex Hematologic Malignancy Management in a TP53-Mutated Patient: Balancing Disease Control and Quality of Life

Cytogenetic and molecular testing revealed a complex karyotype and a TP53 mutation, placing her disease in an adverse-risk category.

  • by

  • April 27, 2026

  • 5 min
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma